109 results
Page 2 of 6
8-K
EX-99.1
g6k48zsa
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
e1dgyz3cts875bx
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-99.2
hir4jsgm6wd38nnyco
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-99.1
v01 ak11g89ep08h
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
8-K
EX-1.1
35m11
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
424B5
hefjasp 4dwvp
17 May 23
Prospectus supplement for primary offering
4:45pm
8-K
EX-99.1
bcj53w4vfg349
15 May 23
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:19am
8-K
EX-99.1
9iayxk213xzy2iujtt
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
jo4jl5x4y1
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
EX-99.1
09lzghljpghu7o9
4 Nov 22
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:22am
8-K
EX-1.1
p80szybi
16 Sep 22
Entry into a Material Definitive Agreement
4:02pm
424B5
8r16g
15 Sep 22
Prospectus supplement for primary offering
5:16pm
424B5
it27l3 p3apd81fk
13 Sep 22
Prospectus supplement for primary offering
5:11pm
8-K
EX-99.1
shsog 0p57
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
u89x1 tpn
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
EX-99.2
woobbsutngwvr
13 Sep 22
Regulation FD Disclosure
9:07am